Back to results
US 11,684,581 B2Granted
Drug and layered silicate composite with improved oral bioavailability, oral pharmacological composition containing the composite and method for producing the composite
AssigneeKorea Institute of Geoscience and Mineral Resources
InventorsIl Mo Kang, Dae Duk Kim, Ju Hwan Park, Ki Min Roh, Jangik Ike Lee, Jae Hwan Kim, Sung Man Seo, Su Young Jung
Life of this patent
Estimating the term…
Abstract
A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.
Claims4
A drug and layered silicate composite comprising:
- layered silicate powders comprising bentonite;
- and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite, wherein a weight of the bentonite is 3 to 5 times a weight of the drug compound, wherein the drug compound includes a sorafenib compound or a salt compound containing the sorafenib compound, wherein the drug and layered silicate composite has a greater release amount and release rate of the drug compound in pH 7.4 buffer than pH 1.2 aqueous solution, wherein the release amount of the drug compound is 2 times or more in the pH 7.4 buffer than in the pH 1.2 aqueous solution.
An oral pharmacological composition containing:
- drug and layered silicate composite powders, wherein the composite powders comprise:
- layered silicate powders comprising bentonite;
- and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite powders;
- and an additive to control uniform distribution of the composite powders in a gastrointestinal tract or to control a release rate of the drug compound in the gastrointestinal tract, wherein a weight of the bentonite is 3 to 5 times a weight of the drug compound, wherein the drug compound includes a sorafenib compound or a salt compound containing the sorafenib compound, wherein the drug and layered silicate composite has a greater release amount and release rate of the drug compound in pH 7.4 buffer than pH 1.2 aqueous solution, wherein the release amount of the drug compound is 2 times or more in the pH 7.4 buffer than in the pH 1.2 aqueous solution.
1 more element
Dependencies are inferred from the claim text.